ReviewThe Journal of clinical endocrinology and metabolism2025
Activin Actions in Adipocytes.
Review in The Journal of clinical endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Intrafollicular activin-A, inhibin-B, and follistatin are associated with in vitro fertilization outcomes in subfertile women.Hormones (Athens, Greece) · 2026Article
- Metainflammation, Mitochondrial Dysfunction, and Organokine Crosstalk: A Central Axis Linking Metabolic Syndrome to Cardiovascular Diseases.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Obesity is a growing global health problem characterized by excess fat accumulation. Though causes of obesity are multifactorial, glucagon-like peptide 1 receptor agonists have emerged as effective weight loss drugs. Nevertheless, these agents are expensive, not uniformly available, and must be used continuously. Moreover, side effects and low efficacy limit the use of these and related molecules in some individuals. Therefore, there is continued interest in characterizing mechanisms regulating adiposity to aid in the development of novel treatments. In recent years, there has been a growing appreciation for ligands of the TGFβ family, the activins, in adipocyte proliferation, differentiation, and function. Here, we review recent progress in understanding the role of these molecules, with a particular focus on the hepatokine, activin E, in lipolysis and diet-induced obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.